Top Alternatives,peptide

Islet amyloid polypeptide (IAPP) structure is a critical area of research due to its profound implications in glucose homeostasis and its association with type 2 diabetes. Also known as amylin, IAPP is a 37-amino acid peptide hormone synthesized and co-secreted with insulin from the pancreatic $\beta$-cells. Understanding its molecular architecture is key to comprehending its normal physiological functions and its pathological role in the formation of islet amyloid.

The islet amyloid polypeptide molecule itself is a 37-residue polypeptide hormone. This peptide is characterized by a specific amino acid sequence that dictates its folding and aggregation properties. Research has revealed that hIAPP comprises 37 amino acids, and its structure is central to its biological activity. Notably, there are no acidic residues in the molecule, and the C-terminus is amidated, contributing to its isoelectric point (pI) being above the pKa of tyrosine (Tyr) and lysine (Lys) residues. This structural feature influences its solubility and interactions.

The aggregation of IAPP into amyloid fibrils is a hallmark of type 2 diabetes. These amyloid deposits, formed from the islet amyloid polypeptide, are found in the pancreatic islets of individuals with this condition and are implicated in $\beta$-cell dysfunction and loss. The structure of these amyloid fibrils is primarily a well-ordered, cross-$\beta$ structure. This highly organized arrangement of polypeptide chains is characteristic of amyloid formation across various diseases.

Recent advancements, including cryo-electron microscopy (cryo-EM), have provided detailed insights into the structure of IAPP fibrils. These studies have elucidated the precise atomic arrangement within the amyloid spine, revealing how the polypeptide chains pack together to form these stable, insoluble aggregates. The structure of the cross-$\beta$ spine of islet amyloid polypeptide has been determined for specific segments of the IAPP molecule, offering a glimpse into the fundamental building blocks of the larger fibril.

The aggregation pathway of IAPP is complex, involving various intermediate structures. While the mature amyloid fibrils exhibit a predominantly $\beta$-sheet conformation, the process of aggregation may involve transient helical structures as well. For instance, some studies suggest that the N-terminal portion of IAPP might adopt a kinked helix motif in certain membrane-bound states, with residues 7-17 and 21-28 forming helical segments and a 310 helix observed from Gly 33 to Asn 35. Conversely, the fragment IAPP 1-7 is believed to possess non-beta-sheet structure due to a disulfide bond between cysteine residues 2 and 7.

The IAPP gene itself, which encodes this crucial polypeptide, consists of at least 3 exons, with the first exon being non-coding and the second encoding the signal peptide and part of the N-terminal region. This genetic basis underlies the production of the IAPP precursor, which is then processed into the mature hormone.

The islet amyloid polypeptide is also referred to as amylin, and its structure and function are closely intertwined. While amylin plays a role in glucose homeostasis, its propensity to aggregate into amyloid structures is what links it to the pathology of type 2 diabetes. IAPP is a highly amyloidogenic polypeptide, meaning it has a strong tendency to misfold and form amyloid aggregates.

The structure of IAPP has also been studied in different species, revealing conserved features. For example, the primary structures of IAPP from humans and various rodents share similarities, although variations exist. The peptide subunit of amyloid found in pancreatic islets of type 2 diabetic patients is indeed IAPP.

Furthermore, the molecular formula for Islet Amyloid Polypeptide has been identified as C165H261N51O55S2, providing a precise chemical description of this 37-amino acid monomeric polypeptide. This detailed understanding of the islet amyloid polypeptide structure is not only fundamental to basic science but also holds promise for the development of therapeutic strategies targeting IAPP aggregation and mitigating the progression of type 2 diabetes. Research continues to explore the intricate details of its folding, aggregation mechanisms, and interactions within the pancreatic $\beta$-cells, paving the way for a deeper comprehension of this vital peptide.